• Voluntary signing of an informed consent form (ICF);

• Males or females, aged 18-70 years (inclusive);

• Pathologically diagnosed with advanced pancreatic cancer or colorectal cancer, having failed or intolerant to at least two lines of standard of care, including metastatic tumors (having received conventional chemotherapy), recurrent tumors (having undergone surgery and adjuvant chemotherapy in the past), or locally advanced tumors with disease progression after neoadjuvant treatment;

• At least one measurable lesion (according to RECIST1.1\[The Response Evaluation Criteria In Solid Tumors\] criteria);

• Patients with tumor tissue or peripheral blood testing positive for KRAS-G12V or G12D mutations and expression of matching HLA-A\*11, C\*01:02, or C\*08:02 subtypes;

• ECOG (Eastern Cooperative Oncology Group)≤2;

• Life expectancy ≥3 months;

• Absolute neutrophil count ≥1×10E9/L;

• Platelet count ≥50×10E9/L, hemoglobin\>90g/dL;

⁃ Absolute lymphocyte count ≥0.5×10E9/L;

⁃ Adequate functional reserve of organs:

∙ Aspartate aminotransferase ≤2.5×ULN (upper limit of normal);

‣ Aspartate transaminase ≤2.5×ULN;

‣ Creatinine clearance ≥60mL/min;

‣ Total serum bilirubin ≤1.5×UNL;

‣ The subject has left ventricular ejection fraction (LVEF) ≥ 50% and no clinically significant pericardial effusion diagnosed by echocardiography;

‣ No clinically significant electrocardiographic abnormality;

‣ Basic oxygen saturation is \>92% under the indoor natural air environment.

⁃ Women of childbearing age must be negative for blood HCG (Human Chorionic Gonadotropin) pregnancy test (by immunofluorescence method) at screening and baseline periods, and agree to use effective contraception for at least 1 year after infusion; and male subjects whose partners are women of childbearing age must agree to use effective barrier contraception methods and avoid sperm donation for at least 1 year after infusion. Contraception must include one highly effective and one additional effective (barrier) method, initiated from screening until at least 1 year after IX001 infusion or until two consecutive flow cytometry tests show the absence of TCR-T cells (whichever occurs later).